Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical protocol for a multicenter, double-blind, randomized, placebo controlled, comparison of the efficacy and safety of Bextra (valdecoxib) 10 mg once daily and naproxen 500 mg twice daily in treating the signs and symptoms of rheumatoid arthritis (RA) in a severe RA population

Next Previous
Trial Profile

Clinical protocol for a multicenter, double-blind, randomized, placebo controlled, comparison of the efficacy and safety of Bextra (valdecoxib) 10 mg once daily and naproxen 500 mg twice daily in treating the signs and symptoms of rheumatoid arthritis (RA) in a severe RA population

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valdecoxib (Primary) ; Naproxen
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 20 Jul 2008 Actual study completion date (1 Jan 2005) added as reported by ClinicalTrials.gov.
  • 16 Apr 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top